Report type: Weekly Strategy
Nikkei Average exceeds 28,000 points, rising cabinet approval ratings and policy expectations
At the end of the fiscal year ending 31st March 2023, the Nikkei Average exceeded the milestone of 28,000 points. This is due to changes in the flow of funds in the foreign exchange market. Amidst the selling of foreign bonds before earnings reports due to portfolio revisions, mainly by regional banks, the dollar-yen exchange rate also began to reverse its rise after the yen appreciated to less than 130 yen per dollar on 24/3. This is partly due to the recent easing of financial system concerns in Europe and the US, leading to a rise in long-term interest rates once again. Against this backdrop, the total amount of reinvestment arising from the increase in dividends paid by listed companies following the recent strengthening of shareholder return policies, including the ex- dividend rights of index-linked ETFs such as TOPIX and the Nikkei Average, has exceeded one trillion yen. This in turn led to futures purchases. Since the lowest price of the Nikkei Average on 30/3 was almost the same as the ex-rights price on the same day, it may be easier for funds to increase their linkage to the index by buying physical shares at the ex-rights price.
In addition to supply and demand factors, there is also a growing sense of relief about Japanese politics. According to a public opinion poll conducted by Nikkei and TV Tokyo from the 24/3 to 26/3, the approval rating for the Kishida Cabinet had risen 5 points from the February survey to 48%, surpassing disapproval by 4 points. Diplomatic achievements, such as PM Kishida’s surprise visit to Ukraine, timed with Chinese President Xi Jinping’s visit to Russia, and the realization of the Japan-Korea summit are believed to have boosted the approval rating.
In the midst of it all, nationwide local elections will be held until 23/4. A “draft plan” that will become PM Kishida’s concrete plan for “extraordinary measures against declining birthrates” is scheduled to be announced on 31/3. The draft plan is likely to include the abolition of income limits on child allowances, expanding the target age range to high school students, the provision of fiduciary support for entrusted child-rearing for newlyweds and child-rearing generations, and the expansion of childcare leave benefits. Another good news is that the lump sum maternity allowance will be raised to 500,000 yen from April.
On 30/3, the “Green Transformation (GX) Promotion Bill” was passed in the House of Representatives plenary session. It includes the introduction of “carbon pricing” which requires companies that emit CO2 to pay a financial burden, as well as the issuance of new government bonds called “GX Economic Transition Bonds” to encourage private investment toward decarbonization. The “GX League”, a voluntary group of companies working to reduce CO2 emissions, is also scheduled to officially begin activities in April. The government is promoting initiatives to offset the portion of greenhouse gas emissions by companies that are difficult to reduce through the purchase of credits and other means. Projects such as forest management and afforestation are therefore expected to be eligible for credits as they absorb CO2. Amid the increasing attention on low PBR (price-to-book ratio) value stocks, companies with large forest holdings such as Oji Holdings (3861) and Nippon Paper Industries (3863) are likely to attract more attention.
In the 3/4 issue, we will be covering Takeda Pharmaceutical (4502), Eisai (4523), Hitachi (6501), and PHC Holdings (6523).
Takeda Pharmaceutical Co., Ltd (4502) 4,350 yen (31/3 closing price)
・Founded in 1781 by Chobei Omiya in Doshomachi, Osaka. Focused on digestive system diseases, rare diseases, immune diseases, cancer, neuropsychiatric diseases, etc. Acquired Ireland’s Shire in 2019 for 6.2 trillion yen.
・For 9M (Apr-Dec) results of FY2023/3 announced on 2/2, revenue increased by 13.9% to 3.0713 trillion yen compared to the same period the previous year, and core operating profit excluding one-time items increased by 26.0% to 954.7 billion yen. Solid performance in key disease areas and yen depreciation contributed to improved results despite the transfer of the Japanese diabetes drug portfolio for 133.0 billion yen, which was recorded in sales in the same period of the previous year.
・For its full year plan, core revenue is expected to increase by 14.9% to 3.93 trillion yen, core operating profit to increase by 23.5% to 1.18 trillion yen, and annual dividend to remain unchanged at 180 yen. In addition to the growth of the biologics market for inflammatory bowel disease and the expansion of market share for the mainstay Entyvio, a treatment for ulcerative colitis and Crohn’s disease, a vaccine for dengue fever (TAK-003), which is estimated to infect 390 million people worldwide, is expected to be launched in Indonesia in 2023.
Eisai Co., Ltd (4523) 7,504 yen (31/3 closing price)
・Toyoji Naito established the Sakuragaoka Laboratory Co., Ltd. in Arakawa-ku, Tokyo in 1936. Develops, manufactures and markets ethical and OTC drugs. Collaborating with Merck of the US in the oncology field and with Biogen of the US in the neurology field related to dementia drugs.
・For 9M (Apr-Dec) results of FY2023/3 announced on 6/2, revenue decreased by 3.4% to 546.197 billion yen compared to the same period the previous year, and operating income decreased by 81.1% to 13.823 billion yen. Company’s global products, including the anti-cancer drug “Lenvima”, have been strong, but a decrease in contract income received from US BMS in the previous period and an increase in profit-sharing to 50% due to the expansion of Lenvima sales have had an impact.
・For its full year plan, revenue is expected to increase by 0.5% to 760.0 billion yen, operating income to increase by 2.3% to 55.0 billion yen, and annual dividend to remain unchanged at 160 yen. Lecanemab, a drug for Alzheimer’s disease (AD), received expedited approval in the US on 6/1 this year. Currently under review by the US FDA (Food and Drug Administration) with a target date of 6/7 for completion of review for full approval. Application filed in Japan on 16/1. At a briefing on 9/3, company forecasted Lecanemab’s FY2030 sales to be in the 1 trillion yen range.
Important Information
This report is prepared and/or distributed by Phillip Securities Research Pte Ltd ("Phillip Securities Research"), which is a holder of a financial adviser’s licence under the Financial Advisers Act, Chapter 110 in Singapore.
By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.
The information and any analysis, forecasts, projections, expectations and opinions (collectively, the “Research”) contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.
Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.
This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient’s own independent verification and exercise of judgment. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.
Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.
Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.
Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.
To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.
The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.
This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.
This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.
IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSE
Where the report contains research analyses or reports from a foreign research house, please note:
